Lushang Freda Pharmaceutical Faces Valuation Shift Amid Declining Financial Performance

Lushang Freda Pharmaceutical Co., Ltd., operating within the realty sector, has recently undergone an adjustment in its evaluation. The company’s valuation score has been revised, reflecting a shift in its financial metrics and market position. The stock currently presents a P/E ratio of 30, indicating a valuation that is perceived as very expensive. Additionally, the Price to Book Value stands at 1.33, while the EV to EBIT and EV to EBITDA ratios are recorded at 17.35 and 10.17, respectively. The company’s dividend yield is noted at 1.07%, and its Return on Capital Employed (ROCE) is 11.01%, with a Return on Equity (ROE) of 4.40%. Despite these metrics, Lushang Freda has faced challenges, including a decline in net sales and operating profit over the past five years, with annual rates of -17.30% and -12.77%, respectively. The company has also reported negative financial performance for the quarter ending March 2026, with net sales and operating profit reaching their lowest levels. This evaluation adjustment highlights the complexities surrounding Lushang Freda's financial landscape. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.